The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with Osteosarcoma.

Détails

ID Serval
serval:BIB_55B5B887B560
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with Osteosarcoma.
Périodique
International journal of molecular imaging
Auteur(s)
Caldarella C., Salsano M., Isgrò M.A., Treglia G.
ISSN
2090-1720 (Electronic)
ISSN-L
2090-1720
Statut éditorial
Publié
Date de publication
2012
Peer-reviewed
Oui
Volume
2012
Pages
870301
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Aim. The objective of this study is to systematically review the role of positron emission tomography (PET) and PET/computed tomography (PET/CT) with fluorine-18-fluorodeoxyglucose (FDG) in assessing the response to neoadjuvant treatment in patients with osteosarcoma (OS). Methods. A comprehensive literature search of published studies through March 2012 in PubMed/MEDLINE, Embase, and Scopus databases regarding whole-body FDG-PET and FDG-PET/CT in patients with OS was performed. Results. Twenty-two studies have investigated the role of FDG-PET and FDG-PET/CT in the evaluation of response to neoadjuvant treatment with either chemotherapy or radiation therapy in patients with OS. The main findings of these studies are presented. Conclusion. FDG-PET or PET/CT seems to be sensitive and reliable diagnostic tools in the assessment of metabolic response to treatment in patients with OS, after baseline PET evaluation has been performed in advance. However, false positive findings due to inflammation in sites of tumoral response should be considered.

Pubmed
Open Access
Oui
Création de la notice
20/08/2017 21:21
Dernière modification de la notice
20/08/2019 15:10
Données d'usage